Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) is a global healthcare solutions provider focused on medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. This news page aggregates company announcements, press releases, and other updates related to GE HealthCare’s business activities and capital markets disclosures.
Visitors can find news about GE HealthCare’s collaborations with health systems, governments, and academic institutions, such as agreements to supply advanced CT scanners under national programs, multi-year care alliances with medical centers, and research initiatives in radiation therapy and oncology. The company also issues news on product and technology developments, including imaging systems, AI-powered reconstruction tools, radiology workflow software, and other innovations that it associates with advancing precision care.
GE HealthCare’s news flow includes corporate and investor-focused items as well. Examples include announcements of upcoming earnings releases, participation in healthcare and investor conferences, and responses to shareholder-related matters such as unsolicited mini-tender offers. These communications provide context on how the company presents its strategy, financing activities, and interactions with the capital markets.
Because GE HealthCare emphasizes integrated solutions across Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, many news items highlight how these businesses work together in specific projects or collaborations. Readers can expect coverage of topics such as AI-enabled imaging, diagnostic access initiatives, training and innovation hubs, and alliances aimed at supporting more efficient and precise care. Investors and observers who follow GEHC news can use this page as a centralized view of the company’s publicly released information and developments over time.
GE HealthCare (Nasdaq: GEHC) warns shareholders to reject an unsolicited mini-tender by Potemkin Limited offering up to 100,000 shares at $45.80 per share. The offer price is ~34.80% below the $70.25 closing price on March 18, 2026.
The company says the offer contains conditions, potential payment delays, and limited withdrawal rights, urges investors to obtain current market quotations, consult advisors, and take no action if they have not tendered.
GE HealthCare (Nasdaq: GEHC) will serve as the industry lead in COMPASS, a five-year, EU-funded IHI consortium with a total budget of €50.5 million and more than 60 partners to advance early detection and prediction of cardiotoxicity in cancer patients across Europe. The grant agreement was signed on March 25, 2026.
COMPASS will combine AI, advanced imaging, biomarkers and integrated care pathways to develop predictive tools, multi-omics biomarkers and an AI-powered clinical decision support pathway aimed at earlier diagnosis and coordinated cardio-oncology care.
GE HealthCare (Nasdaq: GEHC) will showcase cardiology innovations at ACC.26, including the newly U.S. FDA 510(k) cleared Photonova Spectra photon‑counting CT, ReadyFix fleet management for MAC VU360 ECG workstations, a U.S. collaboration with Gentuity, and recent Allia Moveo regulatory clearances.
Highlights emphasize ultra‑high‑definition imaging, AI‑enabled workflows, intravascular visualization, and operational tools intended to improve diagnostic confidence and device uptime across the cardiac care pathway.
GE HealthCare (Nasdaq: GEHC) received U.S. FDA 510(k) clearance for Photonova Spectra, a photon-counting CT system featuring Deep Silicon detectors with 8-bin energy resolution, 0.23s rotation speed, NVIDIA-accelerated reconstruction and a one-scan universal workflow. GE expects its innovation investments to support 1–2% revenue growth.
GE HealthCare (NYSE:GEHC) completed the acquisition of Intelerad for a base purchase price of $2.3 billion in cash, creating a cloud-first, AI-enabled enterprise imaging platform across ambulatory, teleradiology, and hospital settings. Intelerad’s first-year revenue is estimated at $270 million with ~90% recurring revenue and Adjusted EBITDA margin >30%. GE HealthCare expects immediate accretion to top-line growth and EBIT margin, slight short-term dilution to Adjusted EPS inclusive of financing costs, and a high-single-digit ROIC by year five.
GE HealthCare (Nasdaq: GEHC) appointed Kevin A. Lobo, Chair and CEO of Stryker (NYSE: SYK), to its Board of Directors effective March 13, 2026.
Mr. Lobo brings more than 25 years of medtech, operational and financial leadership, including service as Stryker CEO since October 2012 and Stryker board chair since July 2014, and experience at Johnson & Johnson, KPMG, Unilever and Kraft Canada.
GE HealthCare (NYSE:GEHC) announced on March 9, 2026 that View, the diagnostic viewer in the Genesis Radiology Workspace, received U.S. FDA 510(k) clearance. View is a cloud‑native, zero‑footprint diagnostic viewer offering high‑performance 2D/3D visualization, AI‑enabled tools, and direct access to Advanced Visualization in a single workflow.
The product aims to reduce radiologist non‑interpretive time (studies cite up to 44%) and enable remote, secure diagnostic access; availability varies by region.
GE HealthCare (Nasdaq: GEHC) will showcase AI, cloud-first and software solutions at HIMSS Global Health Conference & Exhibition 2026 in Las Vegas, March 9-12, 2026. The company will highlight CareIntellect for Perinatal, Command Center, Genesis Radiology Workspace, Imaging 360, Verisound ultrasound solutions, ViewPoint, and Vscan Air enterprise tools.
GE HealthCare emphasizes AI-enabled clinical workflows, device data interoperability through HL7 Caliper FHIR Accelerator membership, and demonstrations on reducing operational complexity for clinicians.
GE HealthCare (Nasdaq: GEHC) announced FDA 510(k) clearances (Feb 19, 2026) for three next‑generation MR innovations: SIGNA Sprint with Freelium (1.5T sealed, helium‑free), SIGNA Bolt (advanced 3T), and SIGNA One (AI workflow ecosystem).
Key benefits claimed include 1% helium use5‑hour ride‑through, ~30% lower gradient power, up to 65% peak power reduction, up to 34% smaller equipment room, and AI workflow automation to improve throughput and consistency.
GE HealthCare (Nasdaq: GEHC) announced an approximately $35 million expansion to its BARDA cost-share contract to accelerate development of AI-powered point-of-care ultrasound for trauma assessment and mass-casualty preparedness. The agreement builds on an October 2023 program and funds automated AI tools, lung and intra-abdominal assessment features, ruggedized field devices, and clinician evaluation activities to generate clinical evidence.
The expansion is majority-funded by BARDA and includes federal contract number 75A50123C00035.